Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV.
Pediatr Infect Dis J
; 37(6): 595-597, 2018 06.
Article
en En
| MEDLINE
| ID: mdl-29278613
ABSTRACT
We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9-13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Infecciones por Papillomavirus
/
Vacuna Tetravalente Recombinante contra el Virus del Papiloma Humano Tipos 6, 11 , 16, 18
/
Inmunogenicidad Vacunal
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Female
/
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Pediatr Infect Dis J
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
/
PEDIATRIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Canadá